Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 2/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180669 | 0.87 | MME (0.42) | MLYCDLTB4RLTB4R2TAAR1MME | |
| SCHEMBL4174498 | 0.85 | FFAR1 (0.49) | MLYCDLTB4RLTB4R2NPY5RTAAR1 | |
| SCHEMBL4169203 | 0.84 | MLYCD (0.41) | MLYCDLTB4RLTB4R2NPY5RTAAR1 | |
| SCHEMBL4183591 | 0.83 | FFAR1 (0.51) | MLYCDLTB4RLTB4R2NPY5RABCC1 | |
| SCHEMBL4168326 | 0.83 | TDP1 (0.47) | KMT2AKDM4EALDH1A1MMEECE1 | |
| SCHEMBL4175597 | 0.79 | NPSR1 (0.40) | MLYCDLTB4RLTB4R2NPY5RNPSR1 | |
| SCHEMBL4175056 | 0.78 | LTB4R (0.41) | MLYCDLTB4RLTB4R2NPY5RKDM4E | |
| SCHEMBL4174494 | 0.77 | MEN1 (0.46) | MLYCDLTB4RLTB4R2KMT2A | |
| SCHEMBL4189140 | 0.77 | NPSR1 (0.50) | MLYCDLTB4RLTB4R2NPY5RTAAR1 | |
| SCHEMBL4186373 | 0.74 | FFAR1 (0.52) | LTB4RLTB4R2TAAR1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182020-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N--ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | GRUNENTHAL GMBH (DE) | 2009-07-16 | — | — | US | claimed |
| EP-1968935-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | claimed |
| WO-2007079958-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | claimed |
| US-20090182020-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N--ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | GRUNENTHAL GMBH (DE) | 2009-07-16 | — | — | US | disclosed |
| EP-1968935-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007079958-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N-ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182020-A1 | SUBSTITUTED BIS(HETERO)AROMATIC N--ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS | FHIT, CYP3A43, DNPEP | MLYCD 1685/4885LTB4R 3185/4885LTB4R2 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.